Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90


Disentangling compliance with command hallucinations: Heterogeneity of voice intents and their clinical correlates.

Dugré JR, West ML.

Schizophr Res. 2019 Oct;212:33-39. doi: 10.1016/j.schres.2019.08.016. Epub 2019 Aug 23.


Determination of the crystal structure and substrate specificity of ananain.

Yongqing T, Wilmann PG, Pan J, West ML, Brown TJ, Mynott T, Pike RN, Wijeyewickrema LC.

Biochimie. 2019 Jul 12. pii: S0300-9084(19)30202-0. doi: 10.1016/j.biochi.2019.07.011. [Epub ahead of print]


A randomized-controlled trial of treatment for self-stigma among persons diagnosed with schizophrenia-spectrum disorders.

Yanos PT, Lysaker PH, Silverstein SM, Vayshenker B, Gonzales L, West ML, Roe D.

Soc Psychiatry Psychiatr Epidemiol. 2019 Apr 1. doi: 10.1007/s00127-019-01702-0. [Epub ahead of print]


Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction.

Yogasundaram H, Nikhanj A, Putko BN, Boutin M, Jain-Ghai S, Khan A, Auray-Blais C, West ML, Oudit GY.

J Am Heart Assoc. 2018 Nov 6;7(21):e009098. doi: 10.1161/JAHA.118.009098.


Development of a Boston Treatment Program for Youth at Clinical High Risk for Psychosis: Center for Early Detection, Assessment, and Response to Risk (CEDAR).

Friedman-Yakoobian MS, West ML, Woodberry KA, O'Donovan KE, Zimmet SV, Gnong-Granato A, Giuliano AJ, Guyer ME, Rodenhiser-Hill J, Keshavan MS, Seidman LJ.

Harv Rev Psychiatry. 2018 Sep/Oct;26(5):274-286. doi: 10.1097/HRP.0000000000000181.


Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.

Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, Oder D, Watkinson OT, Bichet DG, Khan A, Iwanochko M, Vaz FM, van Kuilenburg ABP, West ML, Hughes DA, Hollak CEM.

J Med Genet. 2018 May;55(5):351-358. doi: 10.1136/jmedgenet-2017-104863. Epub 2018 Feb 7.


Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events.

Beck M, Hughes D, Kampmann C, Pintos-Morell G, Ramaswami U, West ML, Giugliani R.

Mol Genet Metab Rep. 2017 Nov 9;14:31-35. doi: 10.1016/j.ymgmr.2017.10.008. eCollection 2018 Mar.


Clinical insights: Addressing command hallucinations.

West ML.

Schizophr Res. 2018 Jul;197:63-64. doi: 10.1016/j.schres.2017.11.004. Epub 2017 Nov 9. No abstract available.


Oxidized Regenerated Cellulose (Fibrillar) Reduces Risk of Postoperative Corporal Bleeding Following Inflatable Penile Prosthesis Surgery.

Rozanski AT, Viers BR, Liu AG, Shakir NA, Pagliara TJ, Scott JM, West ML, Morey AF.

Urology. 2017 Oct;108:190-194. doi: 10.1016/j.urology.2017.06.002. Epub 2017 Jun 9.


Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease.

Huang J, Khan A, Au BC, Barber DL, López-Vásquez L, Prokopishyn NL, Boutin M, Rothe M, Rip JW, Abaoui M, Nagree MS, Dworski S, Schambach A, Keating A, West ML, Klassen J, Turner PV, Sirrs S, Rupar CA, Auray-Blais C, Foley R, Medin JA.

Mol Ther Methods Clin Dev. 2017 May 12;5:241-258. doi: 10.1016/j.omtm.2017.05.003. eCollection 2017 Jun 16.


Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease.

Shen JS, Arning E, West ML, Day TS, Chen S, Meng XL, Forni S, McNeill N, Goker-Alpan O, Wang X, Ashcraft P, Moore DF, Cheng SH, Schiffmann R, Bottiglieri T.

Hum Mol Genet. 2017 Mar 15;26(6):1182-1192. doi: 10.1093/hmg/ddx032.


Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, West ML, Wanner C; Conference Participants.

Kidney Int. 2017 Feb;91(2):284-293. doi: 10.1016/j.kint.2016.10.004. Epub 2016 Dec 18.


Participation in peer support services and outcomes related to recovery.

Vayshenker B, Mulay AL, Gonzales L, West ML, Brown I, Yanos PT.

Psychiatr Rehabil J. 2016 Sep;39(3):274-81. doi: 10.1037/prj0000178. Epub 2016 Feb 15.


The influence of mental illness and criminality self-stigmas and racial self-concept on outcomes in a forensic psychiatric sample.

West ML, Vayshenker B, Rotter M, Yanos PT.

Psychiatr Rehabil J. 2015 Jun;38(2):150-157. doi: 10.1037/prj0000133. Epub 2015 May 4.


Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease.

Hollander Z, Dai DL, Putko BN, Yogasundaram H, Wilson-McManus JE, Thompson RB, Khan A, West ML, McManus BM, Oudit GY.

Eur J Heart Fail. 2015 Mar;17(3):291-300. doi: 10.1002/ejhf.230. Epub 2015 Jan 23.


Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance.

Smid BE, van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, Timmermans J, Weidemann F, West ML, Biegstraaten M, Lekanne Deprez RH, Florquin S, Postema PG, Tomberli B, van der Wal AC, van den Bergh Weerman MA, Hollak CE.

Int J Cardiol. 2014 Dec 15;177(2):400-8. doi: 10.1016/j.ijcard.2014.09.001. Epub 2014 Sep 20. Review.


Sex steroid blockade enhances thymopoiesis by modulating Notch signaling.

Velardi E, Tsai JJ, Holland AM, Wertheimer T, Yu VW, Zakrzewski JL, Tuckett AZ, Singer NV, West ML, Smith OM, Young LF, Kreines FM, Levy ER, Boyd RL, Scadden DT, Dudakov JA, van den Brink MR.

J Exp Med. 2014 Nov 17;211(12):2341-9. doi: 10.1084/jem.20131289. Epub 2014 Oct 20.


Autophagy gene Atg16L1 prevents lethal T cell alloreactivity mediated by dendritic cells.

Hubbard-Lucey VM, Shono Y, Maurer K, West ML, Singer NV, Ziegler CG, Lezcano C, Motta AC, Schmid K, Levi SM, Murphy GF, Liu C, Winkler JD, Amaravadi RK, Rogler G, Dickinson AM, Holler E, van den Brink MR, Cadwell K.

Immunity. 2014 Oct 16;41(4):579-91. doi: 10.1016/j.immuni.2014.09.011. Epub 2014 Oct 9.


Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up.

van der Tol L, Cassiman D, Houge G, Janssen MC, Lachmann RH, Linthorst GE, Ramaswami U, Sommer C, Tøndel C, West ML, Weidemann F, Wijburg FA, Svarstad E, Hollak CE, Biegstraaten M.

JIMD Rep. 2014;17:83-90. doi: 10.1007/8904_2014_342. Epub 2014 Sep 16.


Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis.

van der Tol L, Svarstad E, Ortiz A, Tøndel C, Oliveira JP, Vogt L, Waldek S, Hughes DA, Lachmann RH, Terryn W, Hollak CE, Florquin S, van den Bergh Weerman MA, Wanner C, West ML, Biegstraaten M, Linthorst GE.

Mol Genet Metab. 2015 Feb;114(2):242-7. doi: 10.1016/j.ymgme.2014.08.007. Epub 2014 Aug 20.


Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.

Auray-Blais C, Blais CM, Ramaswami U, Boutin M, Germain DP, Dyack S, Bodamer O, Pintos-Morell G, Clarke JT, Bichet DG, Warnock DG, Echevarria L, West ML, Lavoie P.

Clin Chim Acta. 2015 Jan 1;438:195-204. doi: 10.1016/j.cca.2014.08.002. Epub 2014 Aug 19.


Altered T-cell entry and egress in the absence of Coronin 1A attenuates murine acute graft versus host disease.

Fulton LM, Taylor NA, Coghill JM, West ML, Föger N, Bear JE, Baldwin AS, Panoskaltsis-Mortari A, Serody JS.

Eur J Immunol. 2014 Jun;44(6):1662-71. doi: 10.1002/eji.201344155.


A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity.

Shono Y, Tuckett AZ, Ouk S, Liou HC, Altan-Bonnet G, Tsai JJ, Oyler JE, Smith OM, West ML, Singer NV, Doubrovina E, Pankov D, Undhad CV, Murphy GF, Lezcano C, Liu C, O'Reilly RJ, van den Brink MR, Zakrzewski JL.

Cancer Discov. 2014 May;4(5):578-91. doi: 10.1158/2159-8290.CD-13-0585. Epub 2014 Feb 18.


Outcomes of patients treated through the Canadian Fabry disease initiative.

Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S, West ML; CFDI investigators.

Mol Genet Metab. 2014 Apr;111(4):499-506. doi: 10.1016/j.ymgme.2014.01.014. Epub 2014 Feb 2.


Intravital imaging of donor allogeneic effector and regulatory T cells with host dendritic cells during GVHD.

Lin KL, Fulton LM, Berginski M, West ML, Taylor NA, Moran TP, Coghill JM, Blazar BR, Bear JE, Serody JS.

Blood. 2014 Mar 6;123(10):1604-14. doi: 10.1182/blood-2013-09-526020. Epub 2014 Jan 10.


CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease.

Coghill JM, Fowler KA, West ML, Fulton LM, van Deventer H, McKinnon KP, Vincent BG, Lin K, Panoskaltsis-Mortari A, Cook DN, Blazar BR, Serody JS.

Blood. 2013 Aug 1;122(5):825-36. doi: 10.1182/blood-2012-06-435735. Epub 2013 Jun 24.


PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD.

Ghosh A, Holland AM, Dogan Y, Yim NL, Rao UK, Young LF, West ML, Singer NV, Lee H, Na IK, Tsai JJ, Jenq RR, Penack O, Hanash AM, Lezcano C, Murphy GF, Liu C, Sadelain M, Sauer MG, Sant'angelo D, van den Brink MR.

Cancer Res. 2013 Aug 1;73(15):4687-96. doi: 10.1158/0008-5472.CAN-12-4699. Epub 2013 Jun 3.


Nrf2 regulates haematopoietic stem cell function.

Tsai JJ, Dudakov JA, Takahashi K, Shieh JH, Velardi E, Holland AM, Singer NV, West ML, Smith OM, Young LF, Shono Y, Ghosh A, Hanash AM, Tran HT, Moore MA, van den Brink MR.

Nat Cell Biol. 2013 Mar;15(3):309-16. doi: 10.1038/ncb2699. Epub 2013 Feb 24.


The central nervous system is a target of acute graft versus host disease in mice.

Hartrampf S, Dudakov JA, Johnson LK, Smith OM, Tsai J, Singer NV, West ML, Hanash AM, Albert MH, Liu B, Toth M, van den Brink MR.

Blood. 2013 Mar 7;121(10):1906-10. doi: 10.1182/blood-2012-09-456590. Epub 2013 Jan 8.


Extrathymic development of murine T cells after bone marrow transplantation.

Holland AM, Zakrzewski JL, Tsai JJ, Hanash AM, Dudakov JA, Smith OM, West ML, Singer NV, Brill J, Sun JC, van den Brink MR.

J Clin Invest. 2012 Dec;122(12):4716-26. doi: 10.1172/JCI60630. Epub 2012 Nov 19.


Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease.

Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, Ghosh A, Tsai JJ, Rao UK, Yim NL, Smith OM, Velardi E, Hawryluk EB, Murphy GF, Liu C, Fouser LA, Kolesnick R, Blazar BR, van den Brink MR.

Immunity. 2012 Aug 24;37(2):339-50. doi: 10.1016/j.immuni.2012.05.028.


Attenuation of acute graft-versus-host disease in the absence of the transcription factor RORγt.

Fulton LM, Carlson MJ, Coghill JM, Ott LE, West ML, Panoskaltsis-Mortari A, Littman DR, Blazar BR, Serody JS.

J Immunol. 2012 Aug 15;189(4):1765-72. doi: 10.4049/jimmunol.1200858. Epub 2012 Jul 9.


Change in internalized stigma and social functioning among persons diagnosed with severe mental illness.

Yanos PT, West ML, Gonzales L, Smith SM, Roe D, Lysaker PH.

Psychiatry Res. 2012 Dec 30;200(2-3):1032-4. doi: 10.1016/j.psychres.2012.06.017. Epub 2012 Jul 3.


Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation.

Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, Liu C, West ML, Singer NV, Equinda MJ, Gobourne A, Lipuma L, Young LF, Smith OM, Ghosh A, Hanash AM, Goldberg JD, Aoyama K, Blazar BR, Pamer EG, van den Brink MR.

J Exp Med. 2012 May 7;209(5):903-11. doi: 10.1084/jem.20112408. Epub 2012 Apr 30.


Group-based treatment for internalized stigma among persons with severe mental illness: findings from a randomized controlled trial.

Yanos PT, Roe D, West ML, Smith SM, Lysaker PH.

Psychol Serv. 2012 Aug;9(3):248-258. doi: 10.1037/a0028048. Epub 2012 Apr 30.


Interleukin-22 drives endogenous thymic regeneration in mice.

Dudakov JA, Hanash AM, Jenq RR, Young LF, Ghosh A, Singer NV, West ML, Smith OM, Holland AM, Tsai JJ, Boyd RL, van den Brink MR.

Science. 2012 Apr 6;336(6077):91-5. doi: 10.1126/science.1218004. Epub 2012 Mar 1.


Prevalence of Internalized Stigma among Persons with Severe Mental Illness.

West ML, Yanos PT, Smith SM, Roe D, Lysaker PH.

Stigma Res Action. 2011 Jan 1;1(1):3-10.


Cardiovascular events in patients with fabry disease natural history data from the fabry registry.

Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, Strotmann J, Tallaj J, Tran TC, West ML, Beitner-Johnson D, Abiose A.

J Am Coll Cardiol. 2011 Mar 1;57(9):1093-9. doi: 10.1016/j.jacc.2010.11.018.


L-selectin is dispensable for T regulatory cell function postallogeneic bone marrow transplantation.

Carlson MJ, Fulton LM, Coghill JM, West ML, Burgents JE, Wan Y, Panoskaltsis-Mortari A, Tedder TF, Blazar BR, Serody JS.

Am J Transplant. 2010 Dec;10(12):2596-603. doi: 10.1111/j.1600-6143.2010.03319.x. Epub 2010 Nov 10.


Therapeutic goals in the treatment of Fabry disease.

Mehta A, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Lidove O.

Genet Med. 2010 Nov;12(11):713-20. doi: 10.1097/GIM.0b013e3181f6e676.


Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.

Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A.

Genet Med. 2010 Nov;12(11):668-79. doi: 10.1097/GIM.0b013e3181f13b75. Review.


Coping, productive time use, and negative mood among adults with severe mental illness: a daily diary study.

Yanos PT, West ML, Smith SM.

Schizophr Res. 2010 Dec;124(1-3):54-9. doi: 10.1016/j.schres.2010.08.020. Epub 2010 Sep 6.


How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?

Auray-Blais C, Ntwari A, Clarke JT, Warnock DG, Oliveira JP, Young SP, Millington DS, Bichet DG, Sirrs S, West ML, Casey R, Hwu WL, Keutzer JM, Zhang XK, Gagnon R.

Clin Chim Acta. 2010 Dec 14;411(23-24):1906-14. doi: 10.1016/j.cca.2010.07.038. Epub 2010 Aug 14.


The immunosuppressive tumor environment is the major impediment to successful therapeutic vaccination in Neu transgenic mice.

Burgents JE, Moran TP, West ML, Davis NL, Johnston RE, Serody JS.

J Immunother. 2010 Jun;33(5):482-91. doi: 10.1097/CJI.0b013e3181d756bb.


Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells.

Coghill JM, Carlson MJ, Panoskaltsis-Mortari A, West ML, Burgents JE, Blazar BR, Serody JS.

Blood. 2010 Jun 10;115(23):4914-22. doi: 10.1182/blood-2009-08-239848. Epub 2010 Feb 25.


Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative.

Sirrs S, Clarke JT, Bichet DG, Casey R, Lemoine K, Flowerdew G, Sinasac DS, West ML.

Mol Genet Metab. 2010 Apr;99(4):367-73. doi: 10.1016/j.ymgme.2009.11.001. Epub 2009 Nov 16.


In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.

Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS.

Blood. 2009 Feb 5;113(6):1365-74. doi: 10.1182/blood-2008-06-162420. Epub 2008 Oct 28.


Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.

Auray-Blais C, Cyr D, Ntwari A, West ML, Cox-Brinkman J, Bichet DG, Germain DP, Laframboise R, Melançon SB, Stockley T, Clarke JT, Drouin R.

Mol Genet Metab. 2008 Mar;93(3):331-40. Epub 2007 Nov 26.


The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease.

Clarke JT, West ML, Bultas J, Schiffmann R.

Genet Med. 2007 Aug;9(8):504-9.


Location and role of free cysteinyl residues in the Sindbis virus E1 and E2 glycoproteins.

Whitehurst CB, Soderblom EJ, West ML, Hernandez R, Goshe MB, Brown DT.

J Virol. 2007 Jun;81(12):6231-40. Epub 2007 Apr 4.

Supplemental Content

Support Center